Results 81 to 90 of about 4,356 (162)

Finerenone: A breakthrough drug for patients of HFmrEF and HFpEF

Journal of the Pakistan Medical Association
Madam, Heart failure (HF) is one of the major cardiovascular diseases, affecting more than 64 million people worldwide.1 HFmrEF and HFpEF are subtypes of HF characterised by LVEFs of 41-49% and >50%, respectively.1 ARBs, ACE inhibitors, aldosterone antagonists and loop diuretics are some of the drug classes that have been used in the management of ...
openaire   +1 more source

P6197Patients with HFrEF, HFmrEF and HFpEF, are they so different? [PDF]

European Heart Journal, 2017
E. Goncalvesova, P. Lesny, M. Luknar, M. Dankova, V. Simovicova, M. Kovacova   +5 more
openaire   +1 more source

Type 2 diabetes increases the risk of mortality and cardiovascular events in ischemic HFmrEF patients: a retrospective cohort study

Diabetology & Metabolic Syndrome
Background Type 2 diabetes mellitus (T2DM) is known to worsen the prognosis of heart failure (HF), but its specific impact on patients with ischemic versus non-ischemic heart failure with mildly reduced ejection fraction (HFmrEF) remains unclear due to ...
Zhican Liu, Hailong Hu, Jianping Zeng, Mingyan Jiang   +3 more
doaj   +1 more source

Prognostic Value of GRACE Score and Left Ventricular Ejection Fraction in Non-ST-Segment Elevation Myocardial Infarction

Journal of Interventional Cardiology
Conclusion: Although the HFrEF subgroup had a higher all-cause mortality rate than did the HFpEF subgroup, all-cause mortality patterns between the HFrEF and HFmrEF subgroups and between the HFmrEF and HFpEF subgroups varied according to the GRACE score.
Yong Hoon Kim, Ae-Young Her, Seung-Woon Rha, Cheol Ung Choi, Byoung Geol Choi, Soohyung Park, Jung Rae Cho, Min-Woong Kim, Ji Young Park, Myung Ho Jeong   +9 more
doaj   +1 more source

Heart failure subgroups: HFrEF, HFmrEF, and HFpEF with or without mitral regurgitation [PDF]

European Heart Journal, 2018
openaire   +2 more sources

Predicting ICU admission in geriatric hip fracture patients with heart failure: the role of O-POSSUM and heart failure subtypes. [PDF]

BMC Geriatr
Bayındır S, Kazez M, Yalın M.
europepmc   +1 more source

Development and Validation of a Prognostic Model to Predict Mortality in Patients With Heart Failure With Mildly Reduced Ejection Fraction After Acute Myocardial Infarction. [PDF]

Cardiol Res
Liu ZC, Zhang LL, Peng L, Zeng JP, Jiang MY.   +4 more
europepmc   +1 more source

Heart Failure With Mildly Reduced Ejection Fraction: A Call for a Precision Medicine Approach. [PDF]

JACC Adv
Wu L, Rizwan A, Rodriguez M, El Hachem K, Hassan Virk HU, Khawaja M, Strauss M, Krittanawong C.   +7 more
europepmc   +1 more source

Differential cardiovascular benefits of SGLT2 inhibitors, sacubitril/valsartan, omecamtiv mecarbil, and vericiguat across heart failure phenotypes: a systematic review and meta-analysis. [PDF]

Front Pharmacol
Wang M, Zuo Z, Wu T, Zhou Z.
europepmc   +1 more source

Trends in Healthcare Costs in Heart Failure and Its Clinical Phenotypes During the Implementation of SGLT2 Inhibitors: A Finnish Registry Study. [PDF]

Clinicoecon Outcomes Res
Hansen JL, Tarkia M, Vasilevska M, Sandin P, Asllanaj E, Wammes K, Mesterton J, Airaksinen KEJ.   +7 more
europepmc   +1 more source